Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients

Purpose: The study aims to evaluate the effectiveness of a tenofovir alafenamide fumarate (TAF) and pegylated interferon alfa (PegIFN-& alpha;) regimen compared to a tenofovir disoproxil fumarate (TDF) and PegIFN-& alpha; therapy in patients with chronic hepatitis B (CHB).Patients and Methods: Patients who were treated with PegIFN-& alpha; in combination with TAF or TDF were retrospectively enrolled. The primary outcome measured was the HBsAg loss rate. The rates of virological response, serological response for HBeAg, and normalization of alanine aminotransferase (ALT) were also calculated. The cumulative incidences of response rates were compared between the two groups using Kaplan-Meier analysis.Results: A total of 114 patients were retrospectively enrolled in the study, with 33 receiving TAF plus PegIFN-& alpha; treatment and 81 receiving TDF plus PegIFN-& alpha; treatment. The HBsAg loss rate for the TAF plus PegIFN-& alpha; group was 15.2% at 24 weeks and 21.2% at 48 weeks, while the TDF plus PegIFN-& alpha; group had rates of 7.4% at 24 weeks and 12.3% at 48 weeks (P=0.204 at 24 weeks, P=0.228 at 48 weeks). In subgroup analysis of HBeAg positive patients, the TAF group had a higher HBsAg loss rate of 25% at week 48, compared to 3.8% in the TDF group (P=0.033). According to Kaplan-Meier analysis, the TAF plus PegIFN-& alpha; group achieved virological response more quickly than the TDF plus PegIFN-& alpha; group (p=0.013). There was no statistical difference in HBeAg serological rate or ALT normalization rate. Conclusion: There was no significant difference in the HBsAg loss between the two groups. However, subgroup analysis revealed that TAF plus PegIFN-& alpha; treatment had a higher HBsAg loss rate than TDF plus PegIFN-& alpha; treatment in HBeAg-positive patients. Additionally, TAF plus PegIFN-& alpha; treatment demonstrated better virological suppression for CHB patients. Therefore, TAF plus PegIFN-& alpha; treatment regimen is recommended for CHB patients who aim to achieve functional cure.

Automated summary

The study compares the effectiveness of TAF and PegIFN-α regimen with TDF and PegIFN-α therapy in CHB patients. The results show that TAF plus PegIFN-α treatment has a higher HBsAg loss rate, quicker virological response, and better ALT normalization compared to TDF plus PegIFN-α treatment.